Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
15 02 2022
Historique:
pubmed: 30 11 2021
medline: 23 3 2022
entrez: 29 11 2021
Statut: ppublish

Résumé

We analyzed risk factors for mortality in febrile neutropenic patients with bloodstream infections (BSI) presenting with septic shock and assessed the impact of empirical antibiotic regimens. A multicenter retrospective study (2010 to 2019) of two prospective cohorts compared BSI episodes in patients with or without septic shock. Multivariate analysis was performed to identify independent risk factors for mortality in episodes with septic shock. Of 1,563 patients with BSI, 257 (16%) presented with septic shock. Those patients with septic shock had higher mortality than those without septic shock (55% versus 15%,

Identifiants

pubmed: 34843387
doi: 10.1128/AAC.01744-21
pmc: PMC8846468
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0174421

Références

Virulence. 2014 Jan 1;5(1):161-9
pubmed: 24157707
Ann Intern Med. 1966 Feb;64(2):328-40
pubmed: 5216294
Lancet Haematol. 2017 Dec;4(12):e573-e583
pubmed: 29153975
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
PLoS One. 2018 Jun 28;13(6):e0199531
pubmed: 29953464
Clin Infect Dis. 2011 Feb 15;52(4):427-31
pubmed: 21205990
Crit Care Med. 2020 Jun;48(6):822-829
pubmed: 32317596
Infection. 2004 Apr;32(2):59-64
pubmed: 15057568
Clin Microbiol Infect. 2019 Apr;25(4):447-453
pubmed: 30096417
Biomed Res Int. 2014;2014:561020
pubmed: 24804223
Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S51-9
pubmed: 17689933
Bone Marrow Transplant. 2020 Mar;55(3):603-612
pubmed: 31570779
Kidney Int. 2020 Jun;97(6):1117-1129
pubmed: 32409237
J Crit Care. 2010 Jun;25(2):276-81
pubmed: 20149587
Antimicrob Agents Chemother. 2003 Sep;47(9):2756-64
pubmed: 12936970
J Clin Oncol. 2013 Aug 1;31(22):2810-8
pubmed: 23752112
J Antimicrob Chemother. 2011 Mar;66(3):657-63
pubmed: 21193475
J Antimicrob Chemother. 2005 Apr;55(4):436-44
pubmed: 15722392
Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3
pubmed: 18778919
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530842
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31405857
Lancet Infect Dis. 2004 Aug;4(8):519-27
pubmed: 15288826
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Crit Care. 2018 Dec 4;22(1):326
pubmed: 30514339
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):497-502
pubmed: 26780692
Crit Care Med. 2010 Jan;38(1):9-15
pubmed: 19829101
Clin Infect Dis. 2020 Mar 3;70(6):1068-1074
pubmed: 31321410
Cochrane Database Syst Rev. 2013 Jun 29;(6):CD003038
pubmed: 23813455
Antimicrob Agents Chemother. 2010 Sep;54(9):3590-6
pubmed: 20585123
Antimicrob Agents Chemother. 2014 Jul;58(7):3799-803
pubmed: 24752269
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Chest. 2014 Nov;146(5):1205-1213
pubmed: 25033349
Korean J Intern Med. 2020 Jul;35(4):979-987
pubmed: 31648434
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Hematology. 2010 Feb;15(1):28-32
pubmed: 20132659
Clin Infect Dis. 2003 May 1;36(9):1103-10
pubmed: 12715303
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0004521
pubmed: 33972253

Auteurs

Mariana Chumbita (M)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Pedro Puerta-Alcalde (P)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Carlota Gudiol (C)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Institut Català d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain.

Nicole Garcia-Pouton (N)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Júlia Laporte-Amargós (J)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain.

Andrea Ladino (A)

Internal Medicine Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Adaia Albasanz-Puig (A)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain.

Cristina Helguera (C)

Internal Medicine Department, Hospital de Cabueñes, Gijon, Spain.

Alba Bergas (A)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Ignacio Grafia (I)

Internal Medicine Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Enric Sastre (E)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

María Suárez-Lledó (M)

Hematology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Xavier Durà (X)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain.

Carlota Jordán (C)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Francesc Marco (F)

Microbiology Department, Centre Diagnòstic Biomèdic, Hospital Clínic, Barcelona, Spain.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Maria Condom (M)

Hematology Department, Institut Català d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Pedro Castro (P)

Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.

Jose A Martínez (JA)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Josep Mensa (J)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Alex Soriano (A)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Jordi Carratalà (J)

Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
REIPI (Spanish Network for Research in Infectious Diseases), Instituto de Salud Carlos III, Madrid, Spain.

Carolina Garcia-Vidal (C)

Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH